Key Updates:

  • On January 19th, Eli Lilly & Co. announced a Complete Response Letter for accelerated approval of donanemab.  Therefore, ICER has removed donanemab from this assessment.
  • As a result of additional information recently becoming available, ICER has decided to extend the timeline for its upcoming report on Alzheimer’s disease, “Beta-Amyloid Antibodies for Early Alzheimer’s Disease” and add lecanemab back into the report.  For more information, click here.
  • ICER decided to extend its timeline for assessing beta-amyloid antibodies for early Alzheimer’s disease pending the biologics license application submissions for donanemab (Eli Lilly & Co.) and lecanemab (Eisai Co., Ltd).  The timeline was updated on August 30, 2022. 

Interventions of Interest:

For questions or to request a Spanish translated Report-at-a-Glance for this assessment, please contact Kelsey Gosselin, Program Manager, at

View the Key Stakeholder List.